Federal contract award
75F40123C00210
EXAMINE THE IMPACT OF A BENZODIAZEPINE (BZD) CARE PLAN (BCP) AND ELECTRONIC HEALTH RECORD (EHR) BZD PRESCRIBING S, IN PARALLEL WITH PROVIDER EDUCATION, ON BZD PRESCRIBING.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $1.2M |
| Current contract value | $1.2M |
| Potential contract value / ceiling | $1.2M |
| Start date | Sep 25, 2023 |
| Current end date | Sep 29, 2026 |
| Potential end date | Sep 29, 2026 |
| Latest award activity | Sep 5, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 5, 2025 | P00006 | $176.4K | EXAMINE THE IMPACT OF A BENZODIAZEPINE (BZD) CARE PLAN (BCP) AND ELECTRONIC HEALTH RECORD (EHR) BZD PRESCRIBING ALERTS, IN PARALLEL WITH PROVIDER EDUCATION, ON BZD PRESCRIBING. |
| Jun 12, 2025 | P00005 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CHANGE THE CONTRACTING OFFICER'S REPRESENTATIVE (COR) FROM MARY JOHNSON TO TARA ARGUAL. |
| Sep 16, 2024 | P00004 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE PERIOD OF PERFORMANCE AND THE KEY PERSONNEL. |
| Aug 20, 2024 | P00003 | $502.2K | BAA FY23C2DWP6 - REDUCING THE USE AND HARMS OF BENZODIAZEPINE TREATMENT THROUGH HEALTH SYSTEM INTERVENTIONS |
| Mar 13, 2024 | P00002 | $0 | BAA FY23C2DWP6 - REDUCING THE USE AND HARMS OF BENZODIAZEPINE TREATMENT THROUGH HEALTH SYSTEM INTERVENTIONS |
| Oct 26, 2023 | P00001 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE DELIVERABLES AND PAYMENT SCHEDULE TO MATCH THE INTENDED FUNDING BY YEAR. |
| Sep 25, 2023 | 0 | $555.3K | EXAMINE THE IMPACT OF A BENZODIAZEPINE (BZD) CARE PLAN (BCP) AND ELECTRONIC HEALTH RECORD (EHR) BZD PRESCRIBING S, IN PARALLEL WITH PROVIDER EDUCATION, ON BZD PRESCRIBING. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 20, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 20, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.